
Surface Oncology Investor Relations Material
Latest events

Q2 2023
2 Aug, 2023

Q1 2023
4 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Surface Oncology Inc
Access all reports
Surface Oncology Inc is a clinical-stage immuno-oncology company dedicated to the development of novel antibody therapies for the treatment of cancer. Its focus lies in creating and advancing treatments designed to modify the tumor microenvironment, thereby supporting and sustaining anti-tumor immune responses. The company's product portfolio includes SRF388, aimed at treating diseases such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, as well as SRF617 for various tumors including gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology is also working on SRF114, NZV930, and GSK4381562 antibodies, alongside conducting research and development activities and pre-clinical studies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
SURF
Country
🇺🇸 United States